ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/BCR-ABL1-inhibitor-second-generation

Search results

target/BCR-ABL1-inhibitor-second-generation
5 trial(s) found.
NCT04925648
ACTRN12623001338651
ACTRN12621000611820
ACTRN12621000991819
Not Applicable
ACTRN12616001187437
Filters
BCR-ABL1
100%
KIT
100%
PDGFRA
100%
SRC
100%
YES1
100%
ALK
40%
CDK4
40%
CDK6
40%
CRAF
40%
EGFR
40%
FLT3
40%
MET
40%
PDGFR
40%
RAF
40%
ROS1
40%
VEGFR
40%
mTOR
40%
mTORC1
40%
AR
20%
androgen axis
20%
ATR
20%
JAK1
20%
JAK2
20%
PI3K
20%
SMO
20%
mTORC2
20%
AXL
20%
ERBB2
20%
FGFR1
20%
FGFR1/2/3
20%
FGFR2
20%
FGFR3
20%
FGFR4
20%
HDAC
20%
IGF1R
20%
MEK
20%
PARP
20%
RET
20%
VEGFR2
20%
proteasome
20%




















 






























	
		
	

    

        

			ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

			
    
			
  • Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
    • 
			
			
  • Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
    • 
			
			
  • No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
    • 
			
			
  • External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.
    • 
			
			


			By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.
			
		

        

            
The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

            
            
Users are free to:

            
    
                
  • Share — copy and redistribute the data in any medium or format
    • 
                
  • Adapt — remix, transform, and build upon the data
    • 
                
  • Use the data for any purpose, including commercial use
    • 
            

            
            
Under the following terms:

            
    
                
  • Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
    • 
                
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
    • 
            

            
            
Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.